Antiatherogenic functionality of high density lipoprotein: How much versus how good

Journal of Atherosclerosis and Thrombosis

Volumn 15, Issue 2, 2008, Pages 52-62

  Sviridov, Dmitri ^a   Mukhamedova, Nigora ^a   Remaley, Alan T ^b   Chin Dusting, Jaye ^a   Nestel, Paul ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Atherosclerosis; Inflammation; Oxidation; Thrombosis

Indexed keywords

EID: 47249113367     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.E571     Document Type: Review

References (100)

1. Wilson PW, Abbott RD, and Castelli WP: High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis, 1988; 8:737-741
2. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, and Dodge HT: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med, 1990; 323:1289-1298
3. Gordon DJ and Fifkind BM: High-density lipoprotein - the clinical implications of recent studies. N Engl J Med, 1989; 321:1311-1316
4. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr., Bangdiwala S, and Tyroler HA: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation, 1989; 79:8-15
5. Johnsen SH, Mathiesen EB, Fosse E, Joakimsen O, Stensland-Bugge E, Njolstad I, and Arnesen E: Elevated High-Density Lipoprotein Cholesterol Levels Are Protective Against Plaque Progression: A Follow-Up Study of 1952 Persons With Carotid Atherosclerosis The Tromso Study. Circulation, 2005; 112:498-504
6. Roma P, Gregg RE, Meng MS, Ronan R, Zech LA, Franceschini G, Sirtori CR, and Brewer HJ: In vivo metabolism of a mutant form of apolipoprotein A-I, apoA-I Milano, associated with familial hypoalphalipoproteinemia. J Clin Invest, 1993; 91:1445-1452
7. Roberts CK, Ng C, Hama S, Eliseo AJ, and Barnard RJ: Effect of a short-term diet and exercise intervention on inflammatory/ anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors. J Appl Physiol, 2006; 101:1727-1732
8. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, and Brewer B; ILLUMINATE Investigators: Effects of Torcetrapib in Patients at High Risk for Coronary Events. N Engl J Med, 2007; 357:2109-2122
9. Sviridov D and Nestel P: Dynamics of reverse cholesterol transport; protection against atherosclerosis. Atherosclerosis, 2002; 161:245-254
10. Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, and Eckardstein A: HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis, 2002; 161:1-16.
11. Nofer J-R, van der Giet M, Tolle M, Wolinska I, Von Wnuck Lipinski K, Baba HA, Tietge UJ, Godecke A, Ishii I, Kleuser B, Schafers M, Fobker M, Zidek W, Assmann G, Chun J, and Levkau B: HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest, 2004; 113:569-581
12. Han R, Lai R, Ding Q, Wang Z, Luo, X, Zhang Y, Cui G, He J, Liu W, and Chen Y. Apolipoprotein A-I stimulates AMP-activated protein kinase and improves glucose metabolism. Diabetologia, 2007; 50:1960-1968
13. Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwei AQ, Vasanji Z, Marsh BJ, Rodrigues B, Johnson JD, Parks JS, Verchere CB, and Hayden MR: Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med, 2007; 13:340-347
14. Abderrahmani A, Niederhauser G, Favre D, Abdelli S, Ferdaoussi M, Yang JY, Regazzi R, Widmann, C, and Waeber G: Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells. Diabetologia, 2007; 50:1304-1314
15. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, Byun J, Vuletic S, Kassim S, Singh P, Chea H, Knopp RH, Brunzell J, Geary R, Chair A, Zhao X-Q, Elkon K, Marcovina S, Ridker P, Oram JF, and Heinecke JW. Shotgun proteomics implicates protease inhibition and complement activation in the anti-inflammatory properties of HDL. J Clin Invest, 2007; 117:746-756
16. Olchawa B, Kingwell BA, Hoang A, Schneider L, Miyazaki O, Nestel P and Sviridov D: Physical Fitness and Reverse Cholesterol Transport. Arterioscler Thromb Vasc Biol, 2004; 24:1087-1091
17. Fournier N, Atger V, Cogny A, Vedie B, Giral P, Simon A, Moatti N, and Paul J: Analysis of the relationship between triglyceridemia and HDL- phospholipid concentrations: consequences on the efflux capacity of serum in the Fu5AH system. Atherosclerosis, 2001; 157:315-323
18. Sviridov D, Chin-Dusting J, Nestel P, Kingwell B, Hoang A, Olchawa B, Starr J, and Dart A: Elevated HDL Cholesterol is Functionally Ineffective in Cardiac Transplant Recipients: Evidence for Impaired Reverse Cholesterol Transport. Transplantation, 2006; 81:361-366
19. Moerland M, Samyn H, van Gent T, Jauhiainen M, Metso J, van Haperen R, Grosveld F, van Tol A, and de Crom R: Atherogenic, enlarged, and dysfunctional HDL in human PLTP/apoA-I double transgenic mice. J Lipid Res, 2007; 48:2622-2631
20. Franceschini G, Calabresi L, Colombo C, Favari E, Bernini F, and Sirtori CR: Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients. Atherosclerosis, 2007; 195:385-391
21. Guerin M, Le Goff W, Frisdal E, Schneider S, Milosavljevic D, Bruckert E, and Chapman MJ: Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux. J Clin Endocrinol Metab, 2003; 88:3738-3746
22. Watanabe H, Soderlund S, Soro-Paavonen A, Hiukka A, Leinonen E, Alagona C, Salonen R, Tuomainen TP, Ehnholm C, Jauhiainen M, and Taskinen MR: Decreased high-density lipoprotein (HDL) particle size, prebeta-, and large HDL subspecies concentration in Finnish low-HDL families: relationship with intima-media thickness. Arterioscler Thromb Vasc Biol, 2006; 26:897-902
23. Wolfrum C, Poy MN, and Stoffel M: Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med, 2005; 11:418-422
24. Kawano, M, Miida T, Fielding CJ, and Fielding PE: Quantitation of pre beta-HDL-dependent and nonspecific components of the total efflux of cellular cholesterol and phospholipid. Biochemistry, 1993; 32:5025-5028
25. Miida T, Miyazaki O, Hanyu O, Nakamura Y, Hirayama S, Narita I, Gejyo F, Ei I, Tasaki K, Kohda Y, Ohta T, Yata S, Fukamachi I, and Okada M: LCAT-Dependent Conversion of Prebeta1-HDL into alpha-Migrating HDL is Severely Delayed in Hemodialysis Patients. J Am Soc Nephrol, 2003; 14:732-738
26. Matsuura F, Wang N, Chen W, Jiang X-C, and Tall AR: HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J Clin Invest, 2006; 116:1435-1442
27. Yvan-Charvet L, Matsuura F, Wang N, Bamberger MJ, Nguyen T, Rinninger F, Jiang X-C, Shear CL, and Tall AR: Inhibition of Cholesteryl Ester Transfer Protein by Torcetrapib Modestly Increases Macrophage Cholesterol Efflux to HDL. Arterioscler Thromb Vasc Biol, 2007; 27:1132-1138
28. Sviridov D, Nestel P, and Watts G: Statins and metabolism of high density lipoprotein. Cardiovasc Hematol Agents Med Chem, 2007; 5:215-221
29. Sviridov D, Hoang A, Ooi E, Watts G, Barrett PH, and Nestel P: Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin. Atherosclerosis, 2008 (in press)
30. Yancey PG, Kawashiri M-a, Moore R, Glick JM, Williams DL, Connelly MA, Rader DJ, and Rothblat GH: In vivo modulation of HDL phospholipid has opposing effects on SR-BI- and ABCA1-mediated cholesterol efflux. J Lipid Res, 2004; 45:337-346
31. Asztalos BF, Collins D, Cupples LA, Demissie S, Horvath KV, Bloomfield HE, Robins SJ, and Schaefer EJ: Value of High-Density Lipoprotein (HDL) Subpopulations in Predicting Recurrent Cardiovascular Events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol, 2005; 25:2185-2191
32. Yancey PG, de la Llera-Moya M, Swarnakar S, Monzo P, Klein SM, Connelly MA, Johnson WJ, Williams DL, and Rothblat GH: High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J Biol Chem, 2000; 275:36596-36604
33. Ohta T, Nakamura R, Ikeda Y, Shinohara M, Miyazaki A, Horiuchi S, and Matsuda I: Differential effect of subspecies of lipoprotein containing apolipoprotein A-I on cholesterol efflux from cholesterol-loaded macrophages: functional correlation with lecithin: cholesterol acyltransferase. Biochim Biophys Acta, 1992; 1165:119-128
34. Huang Y, von Eckardstein A, Wu S, and Assmann G: Cholesterol efflux, cholesterol esterification, and cholesteryl ester transfer by LpA-I and LpA-I/A-II in native plasma. Arterioscler Thromb Vasc Biol, 1995; 15:1412-1418
35. Cavallero E, Brites F, Delfly B, Nicolaiew N, Decossin C, De GC, Fruchart JC, Wikinski R, Jacotot B, and Castro G: Abnormal reverse cholesterol transport in controlled type II diabetic patients. Studies on fasting and post-prandial LpA-I particles. Arterioscler Thromb Vasc Biol, 1995; 15:2130-2135
36. Asztalos BF, Roheim PS, Milani RL, Lefevre M, McNamara JR, Horvath KV, and Schaefer EJ: Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol, 2000; 20:2670-2676
37. Ooi EM, Watts GF, Nestel PJ, Sviridov D, Hoang A, and Barrett PH: Dose-Dependent Regulation of High-Density Lipoprotein Metabolism with Rosuvastatin in the Metabolic Syndrome. J Clin Endocrinol Metab, 2008; 93:430-437
38. Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, and Schaefer EJ: Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients. J Lipid Res, 2002; 43:1701-1707
39. Lee M, Lindstedt LK, and Kovanen PT: Mast cell-mediated inhibition of reverse cholesterol transport. Arterioscler Thromb, 1992; 12:1329-1335
40. Wu Z, Wagner MA, Zheng L, Parks JS, Shy JM, 3rd, Smith JD, Gogonea V, and Hazen SL: The refined structure of nascent HDL reveals a key functional domain for particle maturation and dysfunction. Nat Struct Mol Biol, 2007; 14:861-868
41. Morel DW: Reduced cholesterol efflux to mildly oxidized high density lipoprotein. Biochem Biophys Res Comm, 1994; 200:408-416
42. Hoang A, Murphy AJ, Coughlan MT, Thomas MC, Forbes JM, O'Brien R, Cooper ME, Chin-Dusting JP, and Sviridov D: Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia, 2007; 50:1770-1779
43. Duell PB, Oram JF, and Bierman EL: Nonenzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux. Diabetes, 1991; 40:377-384
44. Pennathur S, Bergt C, Shao B, Byun J, Kassim SY, Singh P, Green PS, McDonald TO, Brunzell J, Chair A, Oram JF, O'Brien K, Geary RL, and Heinecke JW: Human Atherosclerotic Intima and Blood of Patients with Established Coronary Artery Disease Contain High Density Lipoprotein Damaged by Reactive Nitrogen Species. J Biol Chem, 2004; 279:42977-42983
45. Shao B, Oda MN, Bergt C, Fu X, Green PS, Brot N, Oram JF, and Heinecke JW: Myeloperoxidase Impairs ABCA1-dependent Cholesterol Efflux through Methionine Oxidation and Site-specific Tyrosine Chlorination of Apolipoprotein A-I. J Biol Chem, 2006; 281:9001-9004
46. Shao B, Bergt C, Fu X, Green P, Voss JC, Oda MN, Oram JF, and Heinecke JW: Tyrosine 192 in Apolipoprotein A-I Is the Major Site of Nitration and Chlorination by Mycloperoxidase, but Only Chlorination Markedly Impairs ABCA1-dependent Cholesterol Transport. J Biol Chem, 2005; 280:5983-5993
47. Wang WQ, Merriam DL, Moses AS, and Francis GA: Enhanced cholesterol efflux by tyrosyl radical-oxidized high density lipoprotein is mediated by apolipoprotein AI-AII heterodimers. J Biol Chem, 1998; 273:17391-17398
48. Francis GA, Oram JF, Heinecke JW, and Bierman EL: Oxidative tyrosylation of HDL enhances the depletion of cellular cholesteryl esters by a mechanism independent of passive sterol desorption. Biochemistry, 1996; 35:15188-15197
49. Nobecourt E, Davies MJ, Brown BE, Curtiss LK, Bonnet DJ, Charlton F, Januszewski AS, Jenkins AJ, Barter PJ, and Rye KA: The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin: cholesterol acyltransferase. Diabetologia, 2007; 50:643-653
50. Cockcrill GW, Huchns TY, Weerasinghe A, Stocker C, Lerch PG, Miller NE, and Haskard DO: Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation, 2001; 103:108-112
51. Barter PJ, Nicholls S, Rye K-A, Anantharamaiah GM, Navab M, and Fogelman AM: Antiinflammatory Properties of HDL. Circ Res, 2004; 95:764-772
52. Norata GD, Callegati E, Marchesi M, Chiesa G, Eriksson P, and Catapano AL: High-Density Lipoproteins Induce Transforming Growth Factor-{beta}2 Expression in Endothelial Cells. Circulation, 2005; 111:2805-2811
53. Wadham C, Albanese N, Roberts J, Wang L, Bagley CJ, Gamble JR, Rye K-A, Barter PJ, Vadas MA, and Xia P: High-Density Lipoproteins Neutralize C-Reactive Protein Proinflammatory Activity. Circulation, 2004; 109:2116-2122
54. Jambou D, Dejour N, Bayer P, Poiree JC, Fredenrich A, Issa SM, Adjovi DM, Lapalus P, and Harter M: Effect of human native low-density and high-density lipoproteins on prostaglandin production by mouse macrophage cell line P388D1: possible implications in pathogenesis of atherosclerosis. Biochim Biophys Acta, 1993; 1168:115-121
55. Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, Reddy S, Shih D, Shi W, Watson AD, Van Lenten BJ, Vora D, and Fogelman AM: HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol, 2001; 21:481-488
56. Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, and Fogelman AM: High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation, 2001; 103:2283-2288
57. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, Rahmani S, Mottahedeh R, Dave R, Reddy ST, and Fogelman AM: Inflammatory/ antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation, 2003; 108:2751-2756
58. McMahon M, Grossman J, Fitzgerald J, Dahlin-Lee E, Wallace DJ, Thong BY, Badsha H, Kalunian K, Charles C, Navab M, Fogelman AM, and Hahn BH: Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum, 2006; 54:2541-2549
59. Han CY, Chiba T, Campbell JS, Fausto N, Chaisson M, Orasanu G, Plutzky J, and Chair A: Reciprocal and Coordinate Regulation of Serum Amyloid A Versus Apolipoprotein A-I and Paraoxonase-1 by Inflammation in Murine Hepatocytes. Arterioscler Thromb Vasc Biol, 2006; 26:1806-1813
60. Cai L, de Beer MC, de Beer FC, and van der Westhuyzen DR: Serum Amyloid A Is a Ligand for Scavenger Receptor Class B Type I and Inhibits High Density Lipoprotein Binding and Selective Lipid Uptake. J Biol Chem, 2005; 280:2954-2961
61. Miida T, Yamada T, Yamadera T, Ozaki K, Inano K, and Okada M: Serum amyloid A protein generates pre beta 1 high-density lipoprotein from alpha-migrating high-density lipoprotein. Biochemistry, 1999; 38:16958-16962
62. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, and Navab M: Anti-inflammatory HDL becomes proinflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell coculrures. J Clin Invest, 1995; 96:2758-2767
63. Cho KH, Park SH, Park JE, Kim YO, Choi I, Kim JJ, and Kim JR: The function, composition, and particle size of high-density lipoprotein were severely impaired in an oliguric phase of hemorrhagic fever with renal syndrome patients. Clin Biochem, 2008; 41:56-64
64. Kumon Y, Nakauchi Y, Kidawara K, Fukushima M, Kobayashi S, Ikeda Y, Suehiro T, Hashimoto K, and Sipe JD: A longitudinal analysis of alteration in lecithin-cholesterol acyltransferase and paraoxonase activities following laparoscopic cholecystectomy relative to other parameters of HDL function and the acute phase response. Scand J Immunol, 1998; 48:419-424
65. Callegari E, Norata GD, Inoue H, and Catapano AL: Oxidized-HDL3 modulates the expression of Cox-2 in human endothelial cells. Int J Mol Med, 2006; 18:209-213
66. Ahmed W, Orasanu G, Nehra V, Asatryan L, Rader DJ, Ziouzenkova O, and Plutzky J: High-Density Lipoprotein Hydrolysis by Endothelial Lipase Activates PPAR {alpha}: A Candidate Mechanism for High-Density Lipoprotein-Mediated Repression of Leukocyte Adhesion. Circ Res, 2006; 98:490-498
67. Birjmohun RS, van Leuven SI, Levels JHM, van't Veer C, Kuivenhoven JA, Meijers JCM, Levi M, Kastelein JJP, van der Poll T, and Stroes ESG: High-Density Lipoprotein Attenuates Inflammation and Coagulation Response on Endotoxin Challenge in Humans. Arterioscler Thromb Vasc Biol, 2007; 27:1153-1158
68. Charles-Schoeman C, Khanna D, Furst DE, McMahon M, Reddy ST, Fogelman AM, Paulus HE, Park GS, Gong T, and Ansell BJ: Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol, 2007; 34:1459-1464
69. Opole IO, Belmont JM, Kumar A, and Moriarty PM: Effect of low-density lipoprotein apheresis on inflammatory and noninflammatory high-density lipoprotein cholesterol. Am J Cardiol, 2007; 100:1416-1418
70. Banka CL: High density lipoprotein and lipoprotein oxidation. Curr Opin Lipidol, 1996; 7:139-142
71. Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L, Subbanagounder G, Faull KE Reddy ST, Miller NE, and Fogelman AM: Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein. Step 1. J Lipid Res, 2000; 41:1481-1494
72. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, Reddy ST, Sevanian A, Fonarow GC, and Fogelman AM: Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein. Steps 2 and 3. J Lipid Res, 2000; 41:1495-1508
73. Durrington PN, Mackness B, and Mackness MI: Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol, 2001; 21:473-480
74. Terasaka N, Wang N, Yvan-Charvet L, and Tall AR: High-density lipoprotein protects macrophages from oxidized low-density lipoprotein-induced apoptosis by promoting efflux of 7-ketocholesterol via ABCG1. Proceedings of the National Academy of Sciences, 2007; 104:15093-15098
75. Mackness MI, Abbott C, Arrol S, and Durrington PN: The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J, 1993
76. Persegol L, Verges B, Gambert P, and Duvillard L: Inability of HDL from abdominally obese subjects to counteract the inhibitory effect of oxidized LDL on vasorelaxation. J Lipid Res, 2007; 48:1396-1401
77. Navab M, Hama SY, Hough GR Subbanagounder G, Reddy ST, and Fogelman AM: A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res, 2001; 42:1308-1317
78. Tan KC, Chow WS, Lam JC, Lam B, Wong WK, Tam S, and Ip MS: HDL dysfunction in obstructive sleep apnea. Atherosclerosis, 2006; 184:377-382
79. van Leuven SI, Hezemans R, Levels JH, Snoek S, Stokkers PC, Hovingh GK, Kastelein JJP, Stroes ES, de Groot E, and Hommes DW: Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn's disease. J Lipid Res, 2007; 48:2640-2646
80. Yan D, Navab M, Bruce C, Fogelman AM, and Jiang X-C: PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity. J Lipid Res, 2004; 45:1852-1858
81. Kontush A, Chantepie S, and Chapman MJ: Small, Dense HDL Particles Exert Potent Protection of Atherogenic LDL Against Oxidative Stress. Arterioscler Thromb Vasc Biol, 2003; 23:1881-1888.
82. Graham A, Hassall DG, Rafique S, and Owen JS: Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein. Atherosclerosis, 1997; 135:193-204
83. Lakshman MR, Gottipati CS, Narasimhan SJ, Munoz J, Marmillot P, and Nylen ES: Inverse correlation of serum paraoxonase and homocysteine thiolactonase activities and antioxidant capacity of high-density lipoprotein with the severity of cardiovascular disease in persons with type 2 diabetes mellitus. Metabolism, 2006; 55:1201-1206
84. Mertens A, Verhamme P, Bielicki JK, Phillips MC, Quarck R, Verreth W, Stengel D, Ninio E, Navab M, Mackness B, Mackness M, and Holvoet P: Increased Low-Density Lipoprotein Oxidation and Impaired High-Density Lipoprotein Antioxidant Defense Are Associated With Increased Macrophage Homing and Atherosclerosis in Dyslipidemic Obese Mice: LCAT Gene Transfer Decreases Atherosclerosis. Circulation, 2003; 107:1640-1646
85. Daum U, Langer C, Duverger N, Emmanuel F, Benoit P, Denefle P, Chirazi A, Cullen P, Pritchard PH, Bruckert E, Assmann G, and von Eckardstein A: Apolipoprotein A-I (R151C) Paris is defective in activation of lecithin: cholesterol acyltransferase but not in initial lipid binding, formation of reconstituted lipoproteins, or promotion of cholesterol efflux. J Mol Med, 1999; 77:614-622
86. Jia Z, Natarajan P, Forte TM, and Bielicki JK: Thiol-bearing synthetic peptides retain the antioxidant activity of apolipoproteinA-I (Milano). Biochem Biophys Res Comm, 2002; 297:206-213
87. Bielicki JK and Oda MN: Apolipoprotein A-I (Milano) and Apolipoprotein A-I (Paris) Exhibit an Antioxidant Activity Distinct from That of Wild-Type Apolipoprotein A-I. Biochemistry, 2002; 41:2089-2096
88. Vuilleumier N, Charbonney E, Fontao L, Alvarez M, Turck N, Sanchez JC, Burkhard PR, Mensi N, Righini M, Reber G, James RW, Mach F, Chevrolet JC, Dayer JM, Frostegard J, and Roux-Lombard P: Anti-apolipoprotein A-I IgG are associated with high oxidized low-density lipoprotein levels in acute coronary syndrome. Clin Sci (Lond), 2007
89. Mineo C, Deguchi H, Griffin JH, and Shaul PW: Endothelial and Antithrombotic Actions of HDL. Circ Res, 2006; 98:1352-1364
90. Korporaal SJ and Akkerman JW: Platelet activation by low density lipoprotein and high density lipoprotein. Pathophysiol Haemost Thromb, 2006; 35:270-280
91. Naqvi TZ, Shah PK, Ivey PA, Molloy MD, Thomas AM, Panicker S, Ahmed A, Cercek B, and Kaul S: Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. Am J Cardiol, 1999; 84:1011-1017
92. Podrez EA, Byzova TV, Febbraio M, Salomon RG, Ma Y, Valiyaveettil M, Poliakov E, Sun M, Finton PJ, Curtis BR, Chen J, Zhang R, Silverstein RL, and Hazen SL: Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med, 2007; 13:1086-1095
93. Valiyaveettil M, Kar N, Ashraf MZ, Byzova TV, Febbraio M, and Podrez EA: Oxidized high-density lipoprotein inhibits platelet activation and aggregation via scavenger receptor BI. Blood, 2008; 111:1962-1971
94. Zabe M, Feltzer RE, Malle E, Sattler W, and Dean WL: Effects of hypochlorite-modified low-density and high-density lipoproteins on intracellular Ca2+ and plasma membrane Ca(2+)-ATPase activity of human platelets. Cell Calcium, 1999; 26:281-287
95. Li D, Weng S, Yang B, Zander DS, Saldeen T, Nichols WW, Khan S, and Mehta JL: Inhibition of arterial thrombus formation by ApoA1 Milano. Arterioscler Thromb Vasc Biol, 1999; 19:378-383
96. Matsunaga T, Nakajima T, Miyazaki T, Koyama I, Hokari S, Inoue I, Kawai S, Shimomura H, Katayama S, Hara A, and Komoda T: Glycated high-density lipoprotein regulates reactive oxygen species and reactive nitrogen species in endothelial cells. Metabolism, 2003; 52:42-49
97. Gomaraschi M, Baldassarre D, Amato M, Eligini S, Conca P, Sirtori CR, Franceschini G, and Calabresi L: Normal Vascular Function Despite Low Levels of High-Density Lipoprotein Cholesterol in Carriers of the Apolipoprotein A-I Milano Mutant. Circulation, 2007; 116:2165-2172
98. Duell PB, Oram JF, and Bierman EL: Nonenzymatic glycosylation of HDL resulting in inhibition of high-affinity binding to cultured human fibroblasts. Diabetes, 1990; 39:1257-1263
99. Sviridov D, Miyazaki O, Theodore K, Hoang A, Fukamachi I, and Nestel P: Delineation of the Role of Pre-{beta}1-HDL in Cholesterol Efflux Using Isolated Pre-{beta}1-HDL. Arterioscler Thromb Vasc Biol, 2002; 22:1482-1488
100. Sviridov D, Kingwell B, Hoang A, Dart A, and Nestel P: Single Session Exercise Stimulates Formation of Prebeta1-HDL in Leg Muscle. J Lipid Res, 2003; 44:522-526